Prognostic Value of Proliferating Cell Nuclear Antigen Indexin Gastric Stromal Tumors:<i>Correlation With Mitotic Count and Clinical Outcome</i>

Amin, Mahual B.; Chan, Kevin M.; Linden, Michael D.; Kubus, James; Zarbo, Richard J.

doi:10.1093/ajcp/100.4.428

Cited by 119 publications

(61 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eighteen tumors had more than 10 cm in maximal diameter that is alone one of the main prognostic factor (9,15) . Almost half of the tumors had also more than 5 mitoses/per HPF that is also a factor of worst prognosis (2,28,29) . The literature articles related that up to 20% of GISTs tumors had a high malignant potential (10,28) , however in this study this potential arise to 80%.…”

Section: Discussionmentioning

confidence: 99%

“…The biological potential (2,10,28,29) was determined by the tumor size and the mitotic index (Table 1). Tumor size was recorded as the largest diameter in any dimension of the primary tumor and was stratified as ≤5 cm, 5 to 10 cm or >10 cm.…”

Section: Methodsmentioning

confidence: 99%

“…Tumor size and mitotic index are the common prognostic factors used. Tumors with more than 10 cm (9,15) or with more than five mitosis (2,28,29) per 50 high power field (HPF) had worst prognosis. Mostly in this group of patients, the use of imatinib, a c-KIT inhibitor as an adjuvant treatment has been studied (5,6,7,10,20,29) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Neves¹,

Oshima²,

Neto³

et al. 2009

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor. Cellular proliferation and apoptosis is gaining importance for predicting prognosis in several cancers. Objective -To investigate the Ki67 and p53 immunostaining in GISTs. Methods -Specimens from 40 patients with GIST were assessed for immunohistochemical expression of Ki67 and p53. The tumors were divided according the risk of recurrence in two groups: I with high or intermediate risk and; II with low or very low risk. Results -Among the 40 patients, 21 were men, the mean age was 56 years, 16 occurred in the small intestine and 13 in the stomach, 5 in the retroperitonium, 4 in the colon or rectum and 2 in the mesenterium. Thirty two tumors were from group I and 8 from group II. Half of the patients developed recurrence, being 90% of the group I (P = 0.114). The tumor Ki67 labelling index ranged from 0.02 to 0.35 (mean level 0.12). This index was marginally higher in the group I patients with recurrence (P = 0.09) compared to the patients of the same group without recurrence. p53 staining was expressed in 65% of the GISTs. A higher frequency of p53 and Ki67 had been found in the group I tumors when compared to the other group (P = 0.022; OR = 8.00 -IC 95%: 1.32-48.65). Conclusion -The most common site was the small intestine and 80% had a malignant potential justifying the high recurrence observed. No significant correlation was found between p53 and overall outcome of the patients. In group I patients, the evaluation Ki67LI may be a marker of prognosis. The positivity of both markers is higher among the patients with worst prognosis than in the others. HEADINGS -Gastrointestinal stromal tumors. Ki-67 antigen. Tumor suppressor protein p53.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Neves¹,

Oshima²,

Neto³

et al. 2009

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Amin et al (1993) dividieron a los GISTs en 3 grupos: 1.Benignos: menos de 5 mitosis por cada 50 campos de gran aumento (cga) y tamaño tumoral de 5 cm. o menos.…”

Section: Discussionunclassified

Expresión Inmunohistoquímica de Vimentina, CD 34 y c-Kit (CD 117) en Tumores Estromales Gastrointestinales (GISTs)

Fonseca¹,

Guerini²,

Gramática³

et al. 2010

Int. J. Morphol.

View full text Add to dashboard Cite

RESUMEN:Los tumores estromales gastrointestinales (GISTs) comprenden a tumores de origen mesenquimal que antes eran clasificados como "tumores del músculo liso", no obstante los avances en el campo de la microscopía electrónica e inmunohistoquímica han permitido su diferenciación. Derivan de las células intersticiales de Cajal, representan el 1-2% de todas las neoplasias del tubo digestivo y son más frecuentes en personas mayores de 40 años, con igual incidencia en ambos sexos. Se estudiaron 30 casos de GISTs en un análisis prospectivo y retrospectivo, en el período comprendido entre los años 1987 y 2007. Para el material retrospectivo se estudiaron bloques de tejidos en parafina. El material se fijó en formaldehído al 10% y se incluyó en parafina, realizando tinciones habituales con H&E y técnicas histoquímicas (P.A.S y tricrómico de Masson). Se realizó, además, panel inmunohistoquímico: Vimentina, Actina de músculo liso, CD-34 y c-Kit (CD-117). Con el fin de estudiar las características anatomopatológicas, en relación a la sintomatología clínica que presentan los GISTs, se observó el comportamiento de los mismos teniendo en cuenta diferentes variables. Con respecto a la inmunohistoquímica, la vimentina fue positiva en el 100 % de los casos, mientras que CD-34 y CD-117 fueron positivos en aproximadamente el 90 %. La tendencia de estos tumores a seguir un curso clínico impredecible, con riesgo de recidiva tardía y de metástasis, hace recomendable el seguimiento del paciente regularmente y por un período indefinido. El haber tenido la oportunidad de estudiar 30 pacientes portadores de GISTs mediante la implementación de técnicas inmunohistoquímicas, a los fines de confirmar la histogénesis tumoral, motivan la presente comunicación.

show abstract

“…However, if an adequate sample can be obtained, it is possible to count mitotic figures, the most significant indicator of biologic behavior [33,34]. By using the EUS-FNA technique, adequate specimens are usually obtained for histology and differential immunophenotyping of GISTs.…”

Section: Gastrointestinal Stromal Tumors (Gist)mentioning

confidence: 99%

Molecules and markers for endosonographers: What do we need to know and measure?

Al‐Haddad

Wallace²

2006

Endoscopy

View full text Add to dashboard Cite

IntroductionEndoscopic ultrasound (EUS) has become an indispensable tool for the diagnosis and staging for gastrointestinal and thoracic malignancies. Thanks to the safety and reliability of fine needle aspiration (FNA), this has become the method of choice for tissue acquisition from lymph nodes and tumors in various locations within the thoracic and abdominal cavities.In the recent years, EUS-FNA has offered a better understanding of the pathophysiology of cancer. Similar to the adenoma-carcinoma sequence, other cancers including pancreas, lung, and esophagus may follow a comparable multi-step process of carcinogenesis. A necessary component of these is the ability to go ªbeyond cytologyº to use fine needle aspirates to characterize the genomic and proteomic profiles of cancer and precancerous tissue. Molecular characterization of FNA samples: The basic conceptsAlthough DNA is relatively stable in excised tissue, proteins and particularly RNA are unstable and must be handled in special ways to preserve them for characterization. The first role of the endoscopist is to obtain and preserve tissue suitable for further molecular characterization. In the first part of this review, we will focus on these initial steps. The methods for genomic and proteomic analyses are beyond the scope of this article and interested readers are referred to recent reviews [1,2].RNA destroying-enzymes (RNAase enzymes) are very ubiquitous in the environment. Therefore, it is imperative to prevent rapid degradation of RNA in order to preserve fine needle aspirates for genomic studies. The simplest method to do this is through the use of RNAase inhibitor solutions such as RNA-later (Quagen Inc. Valencia Ca, USA) or RNA Stat 60 (RNA STAT-60 ; TEL-TEST, Friendswood, TX, USA). The needle aspirate can be quickly mixed with these reagents. In our laboratory, we immediately place the FNA sample into an eppendorf tube in a wet ice bath, centrifuge in a small desktop device in the EUS room (1000 RPM at 4 deg. C, 1 minute), remove the supernatant, and resuspend the cell pellet in RNA stat 60. If RNA stabilization is not available on-site, the aspirate can also be snap frozen in liquid nitrogen and stored (preferably at ±70 to ±80C) for later RNA stabilization. Every effort should be made to handle the specimen in an RNAase-free environment including clean gloves and a surface that has been cleaned with an RNAase inhibitor solution.In the remainder part of this review, we will focus on organspecific applications of the biological markers. This will include lesions of the pancreas and gastrointestinal stromal tumors (GIST). The use of biomarkers in staging non-small call lung cancer will be discussed in a separate review. Pancreatic lesionsDiagnosis of early pancreatic cancer remains a challenge mainly due to the lack of a standard screening test. Therefore, improving long-term survival relies primarily on detecting and treating early pancreatic cancer and thus reducing the incidence of pancreatic cancer.EUS is increasingly considered a valuable to...

show abstract

Prognostic Value of Proliferating Cell Nuclear Antigen Indexin Gastric Stromal Tumors:Correlation With Mitotic Count and Clinical Outcome

Cited by 119 publications

References 0 publications

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Ki67 and p53 in gastrointestinal stromal tumors - GIST

Expresión Inmunohistoquímica de Vimentina, CD 34 y c-Kit (CD 117) en Tumores Estromales Gastrointestinales (GISTs)

Molecules and markers for endosonographers: What do we need to know and measure?

Contact Info

Product

Resources

About